Get the Stockscreener App
218.00
0.27%
-0.40
Overview
News
Price History
Option Chain
Financials
Why RMD Down?
Discussions
Forecast
Stock Split
Dividend History
Resmed Inc stock is traded at $218.00, with a volume of 753.12K.
It is down -0.27% in the last 24 hours and up +11.11% over the past month.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks, and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with aging populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two-thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan, and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor, and payer in the out-of-hospital setting.
See More
Previous Close:
$218.40
Open:
$219.34
24h Volume:
753.12K
Relative Volume:
0.53
Market Cap:
$31.62B
Revenue:
$5.54B
Net Income/Loss:
$1.52B
P/E Ratio:
21.02
EPS:
10.3734
Net Cash Flow:
$1.74B
1W Performance:
+11.77%
1M Performance:
+11.11%
6M Performance:
-12.24%
1Y Performance:
-15.05%
1-Day Range:
$216.52
$219.98
1-Week Range:
$196.99
$222.43
52-Week Range:
$180.26
$293.81
Resmed Inc Stock (RMD) Company Profile
Name
Resmed Inc
Sector
Industry
Phone
(858) 746-2400
Address
9001 SPECTRUM CENTER BLVD., SAN DIEGO, CA
Compare RMD vs ISRG, BDX, MDLN, ALC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RMD
Resmed Inc
|
218.00 | 31.68B | 5.54B | 1.52B | 1.74B | 10.37 |
ISRG
Intuitive Surgical Inc
|
426.23 | 153.29B | 10.58B | 3.00B | 2.83B | 8.2437 |
BDX
Becton Dickinson Co
|
157.10 | 42.86B | 21.37B | 1.41B | 3.07B | 3.9437 |
MDLN
Medline Inc
|
42.91 | 36.15B | 29.14B | 1.07B | 1.05B | 1.1956 |
ALC
Alcon Inc
|
66.95 | 33.32B | 10.63B | 819.00M | 1.59B | 1.6577 |
Resmed Inc Stock (RMD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-15-26 | Initiated | JP Morgan | Overweight |
| Dec-16-25 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Sep-18-25 | Initiated | Citigroup | Buy |
| Sep-02-25 | Upgrade | CLSA | Hold → Outperform |
| Jul-15-25 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Mar-19-25 | Initiated | Morgan Stanley | Overweight |
| Jan-16-25 | Initiated | Goldman | Buy |
| Jan-10-25 | Initiated | Piper Sandler | Neutral |
| Dec-13-24 | Initiated | Stifel | Hold |
| Sep-24-24 | Initiated | Robert W. Baird | Outperform |
| Sep-18-24 | Downgrade | Wolfe Research | Peer Perform → Underperform |
| Sep-04-24 | Downgrade | Needham | Buy → Hold |
| Jun-25-24 | Downgrade | Oppenheimer | Outperform → Perform |
| Jun-24-24 | Downgrade | Citigroup | Buy → Neutral |
| Feb-06-24 | Resumed | KeyBanc Capital Markets | Overweight |
| Oct-27-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-12-23 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Oct-09-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Sep-29-23 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Sep-06-23 | Upgrade | Needham | Hold → Buy |
| Sep-05-23 | Downgrade | UBS | Buy → Neutral |
| Aug-01-23 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| May-23-23 | Initiated | UBS | Buy |
| Apr-14-23 | Initiated | Mizuho | Buy |
| Jan-17-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Oct-28-22 | Downgrade | Citigroup | Buy → Neutral |
| Oct-20-22 | Upgrade | BofA Securities | Neutral → Buy |
| Oct-12-22 | Initiated | Jefferies | Hold |
| Sep-08-22 | Upgrade | Citigroup | Neutral → Buy |
| Aug-15-22 | Downgrade | CLSA | Buy → Outperform |
| Aug-12-22 | Downgrade | Citigroup | Buy → Neutral |
| Aug-12-22 | Downgrade | JP Morgan | Overweight → Neutral |
| Aug-12-22 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Jun-06-22 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Apr-06-22 | Initiated | Wolfe Research | Outperform |
| Jan-31-22 | Upgrade | Citigroup | Neutral → Buy |
| Jan-31-22 | Upgrade | Goldman | Neutral → Buy |
| Jan-28-22 | Upgrade | RBC Capital Mkts | Underperform → Sector Perform |
| Jan-24-22 | Upgrade | BofA Securities | Underperform → Neutral |
| Jan-24-22 | Upgrade | JP Morgan | Neutral → Overweight |
| Jan-13-22 | Upgrade | CLSA | Outperform → Buy |
| Jan-13-22 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Dec-21-21 | Upgrade | KeyBanc Capital Markets | Sector Weight → Overweight |
| Dec-06-21 | Upgrade | Macquarie | Neutral → Outperform |
| Oct-22-21 | Upgrade | CLSA | Underperform → Outperform |
| Aug-02-21 | Downgrade | CLSA | Outperform → Sell |
| Aug-02-21 | Downgrade | Needham | Buy → Hold |
| Jul-28-21 | Upgrade | Jefferies | Underperform → Hold |
| Jul-26-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-14-21 | Initiated | RBC Capital Mkts | Underperform |
| Jun-28-21 | Downgrade | Citigroup | Buy → Neutral |
| Jun-22-21 | Upgrade | Macquarie | Neutral → Outperform |
| Jun-22-21 | Initiated | Robert W. Baird | Neutral |
| Jun-21-21 | Reiterated | Needham | Buy |
| Jun-16-21 | Downgrade | BofA Securities | Neutral → Underperform |
| Jun-09-21 | Upgrade | CLSA | Sell → Outperform |
| May-21-21 | Upgrade | JP Morgan | Neutral → Overweight |
| May-11-21 | Upgrade | Citigroup | Neutral → Buy |
| Apr-30-21 | Downgrade | Citigroup | Buy → Neutral |
| Mar-16-21 | Upgrade | Needham | Hold → Buy |
| Nov-02-20 | Upgrade | UBS | Neutral → Buy |
| Oct-30-20 | Upgrade | JP Morgan | Underweight → Neutral |
| Oct-27-20 | Upgrade | BofA Securities | Underperform → Neutral |
| Aug-07-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jun-17-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| May-01-20 | Downgrade | JP Morgan | Neutral → Underweight |
| May-01-20 | Upgrade | Oppenheimer | Perform → Outperform |
| Feb-18-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Feb-03-20 | Initiated | CLSA | Underperform |
| Jan-31-20 | Downgrade | UBS | Buy → Neutral |
| Jan-10-20 | Initiated | Oppenheimer | Perform |
| Nov-22-19 | Initiated | KeyBanc Capital Markets | Sector Weight |
| Jul-29-19 | Upgrade | UBS | Neutral → Buy |
| Jul-16-19 | Downgrade | UBS | Buy → Neutral |
| May-06-19 | Upgrade | UBS | Neutral → Buy |
| Apr-18-19 | Upgrade | JP Morgan | Underweight → Neutral |
| Jan-25-19 | Downgrade | Goldman | Buy → Neutral |
| Jan-25-19 | Downgrade | JP Morgan | Neutral → Underweight |
| Oct-26-18 | Upgrade | Credit Suisse | Neutral → Outperform |
| Jul-02-18 | Initiated | Goldman | Buy |
View All
Resmed Inc Stock (RMD) Latest News
Form 144 RESMED INC For: 7 July By Investing.com - Investing.com Canada
Michael Farrell to sell 4,991 RMD shares (NYSE: RMD) - Stock Titan
ResMed stock trades on Nasdaq. Focus stays on sleep apnea demand. - AD HOC NEWS
Why Resmed (RMD) Stock Is Up Today - Moomoo
ResMed Inc (RMD) Shares Surge 4.2% -- What GF Score of 90 Tells Investors - GuruFocus
ResMed Inc. stock rises Monday, outperforms market - MarketWatch
RMDResmed Inc Options - Finviz
ResMed Inc. (RMD) Stock Analysis: A 24% Upside Potential With Robust Revenue Growth - DirectorsTalk Interviews
Precision Trading with Resmed Inc. (RMD) Risk Zones - Stock Traders Daily
Ord Minnett Sticks to Their Buy Rating for Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh (RMD) - The Globe and Mail
ResMed (RMD) Is Up 5.6% After Russell Growth Index Removal Amid Brighter Analyst Outlook - Sahm
Why ResMed (RMD) Stock Is Trading Up Today - Yahoo Finance
ResMed Inc. stock rises Thursday, outperforms market - MarketWatch
ResMed (RMD) Added to Goldman Sachs' APAC Conviction List - GuruFocus
Is It Too Late to Buy ResMed Inc (RMD) After 3.2% Rally? GF Value Says Undervalued - GuruFocus
ResMed Inc. stock rises Wednesday, outperforms market - MarketWatch
ResMed (RMD) Upgraded to Buy: Here's Why - Yahoo Finance UK
Wall Street Analysts Think ResMed (RMD) Could Surge 28.21%: Read This Before Placing a Bet - Yahoo! Finance Canada
ResMed (NYSE: RMD) reports 1.95% stake in Nyxoah — 1.94M shares - Stock Titan
ResMed (RMD) Stock Looks Cheap Even As The Market Stays Cautious - Yahoo Finance
Resmed to report Q4FY26 earnings on August 6, 2026 - scanx.trade
Should ResMed’s Russell Growth Index Exit and Volatility Spike Require Action From ResMed (RMD) Investors? - Yahoo Finance
ResMed Gets PTAB To Ax 1 Out Of 2 Sleep Apnea Patents - Law360
ResMed Inc. stock falls Tuesday, underperforms market - MarketWatch
Resmed to Report Fourth Quarter Fiscal 2026 Earnings on August 6, 2026 - The Manila Times
ResMed Inc options activity points to a potential volatility spike. Consensus earnings expectations - AD HOC NEWS
ResMed leads sleep apnea market with strong growth and margin improvements, rated Buy with 12% safety margin. - Pluang
ResMed: Fear-Driven Selloff Creates A Compelling Margin Of Safety Entry Point - Seeking Alpha
ResMed Inc.(NYSE: RMD) dropped from Russell Midcap Growth Benchmark - marketscreener.com
Are Options Traders Betting on a Big Move in ResMed Stock? - TradingView
ResMed adjusts index footprint, shares hold gains on NYSE and ASX - AD HOC NEWS
ResMed Inc.(NYSE: RMD) dropped from Russell 3000E Growth Benchmark - marketscreener.com
ResMed Inc.(NYSE: RMD) dropped from Russell 1000 Growth Benchmark - marketscreener.com
Daily Brief Australia: Cochlear Ltd, Commonwealth Bank of Australia, Fortescue Metals, ResMed Inc and more - Smartkarma
ResMed Inc.(NYSE: RMD) dropped from Russell 3000 Growth Benchmark - marketscreener.com
AirSense 10 ClimateLineAir Heated Tube from ResMed Inc.quieter nights with smarter humidity - Ad-hoc-news.de
ResMed muted ahead of next earnings, shares trade steadily on NYSE - Ad-hoc-news.de
Enterprise value to EBIT forward of ResMed Inc. – NYSE:RMD - TradingView
OLD National Bancorp IN Has $4.58 Million Position in ResMed Inc. $RMD - MarketBeat
ResMed Inc. sees fresh institutional buying, shares hover near 200 dollars - Ad-hoc-news.de
ResMed Inc. CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh - TradingView
Price to earnings forward of ResMed Inc. – NYSE:RMD - TradingView
Price to earnings forward of ResMed Inc. CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh – MUN:RMEA - TradingView
Price to sales forward of ResMed Inc. – NYSE:RMD - TradingView
ResMed clears key trading range, shares hold firm between support and resistance - Ad-hoc-news.de
Enterprise value to revenue forward of ResMed Inc. – NYSE:RMD - TradingView
Should you continue to hold Resmed stock in your portfolio? - MSN
ResMed clears a fresh 52-week high, shares extend their Nasdaq run - Ad-hoc-news.de
Why ResMed Inc (RMD) Is Set to Outperform the Market: Insights i - GuruFocus
Price to book forward of ResMed Inc. – NYSE:RMD - TradingView
ResMed Stock is Down 20% in 2026. Is It a Buying Opportunity or a Warning Sign? - TIKR.com
Resmed Inc Stock (RMD) Financials Data
Revenue
Net Income
Cash Flow
EPS
Resmed Inc Stock (RMD) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Farrell Michael J. | Chairman and CEO |
Jun 08 '26 |
Sale |
193.96 |
4,991 |
968,064 |
466,256 |
2.04%
0.48%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):